Arvinas to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5.
Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARVN declined 0.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:
- Wells Fargo Healthcare Conference on Thursday, September 4. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
- Cantor Global Healthcare Conference on Friday, September 5. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When is Arvinas (ARVN) presenting at the Wells Fargo Healthcare Conference 2025?
When is Arvinas (ARVN) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Arvinas (ARVN) conference presentations in September 2025?
What type of company is Arvinas (ARVN)?
